BI Asset Management Fondsmaeglerselskab’s Indivior Pharmaceuticals INDV Stock Holding History

BI Asset Management Fondsmaeglerselskab’s Portfolio INDV Stock Details INDV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.63M	Buy	+39,832	New	+$1.44M	0.01%	457

Other funds holding INDV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

CAM

Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Danske Bank Copenhagen K, Denmark $50.6B AUM 42.84% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

BI Asset Management Fondsmaeglerselskab's INDV Position: Q2 2026 in Review

BI Asset Management Fondsmaeglerselskab opened a new position in Indivior Pharmaceuticals (INDV) in Q2 2026: 39,832 shares worth $1.63M. The stake represents 0.01% of the portfolio and ranks #457 among its holdings.

141 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

BI Asset Management Fondsmaeglerselskab held 39,832 shares of Indivior Pharmaceuticals worth $1.63M as of Q2 2026.
Indivior Pharmaceuticals was a new BI Asset Management Fondsmaeglerselskab position in Q2 2026.
Indivior Pharmaceuticals made up 0.01% of BI Asset Management Fondsmaeglerselskab's portfolio in Q2 2026, its #457 holding.
141 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on BI Asset Management Fondsmaeglerselskab's 13F filing for Q2 2026, filed 10 Aug 2026.